309
Views
0
CrossRef citations to date
0
Altmetric
REVIEW

A Review of Randomized Controlled Trials of Hereditary Angioedema Long-Term Prophylaxis with C1 Inhibitor Replacement Therapy: Alleviation of Disease Symptoms Is Achievable

& ORCID Icon
Pages 269-277 | Received 05 Nov 2022, Accepted 01 Feb 2023, Published online: 09 Mar 2023

References

  • Bygum A, Busse P, Caballero T, Maurer M. Disease severity, activity, impact, and control and how to assess them in patients with hereditary angioedema. Front Med. 2017;4:212. doi:10.3389/fmed.2017.00212
  • Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update. Allergy. 2022;77(7):1961–1990. doi:10.1111/all.15214
  • Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267–274. doi:10.1016/j.amjmed.2005.09.064
  • Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol. 2006;154(3):542–545. doi:10.1111/j.1365-2133.2005.07048.x
  • Csuka D, Veszeli N, Imreh E, et al. Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency. Orphanet J Rare Dis. 2015;10:132. doi:10.1186/s13023-015-0351-5
  • Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol. 1999;104(6):1321–1322. doi:10.1016/S0091-6749(99)70030-8
  • Levi M, Cohn DM, Zeerleder S. Hereditary angioedema: linking complement regulation to the coagulation system. Res Pract Thromb Haemost. 2019;3(1):38–43. doi:10.1002/rth2.12175
  • Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3suppl):S51–S131. doi:10.1016/j.jaci.2004.06.047
  • Busse PJ, Christiansen SC. Hereditary angioedema. N Engl J Med. 2020;382(12):1136–1148. doi:10.1056/NEJMra1808012
  • Levy D, Craig T, Keith PK, Krishnarajah G, Beckerman R, Prusty S. Co-occurrence between C1 esterase inhibitor deficiency and autoimmune disease: a systematic literature review. Allergy Asthma Clin Immunol. 2020;16:41. doi:10.1186/s13223-020-00437-x
  • Brickman CM, Tsokos GC, Balow JE, et al. Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol. 1986;77(5):749–757. doi:10.1016/0091-6749(86)90424-0
  • Ballanti E, Perricone C, Greco E, et al. Complement and autoimmunity. Immunol Res. 2013;56(2–3):477–491. doi:10.1007/s12026-013-8422-y
  • Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132–150. doi:10.1016/j.jaip.2020.08.046
  • Hack CE, Relan A, van Amersfoort ES, Cicardi M. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy. 2012;67(1):123–130. doi:10.1111/j.1398-9995.2011.02716.x
  • Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(1):58–64. doi:10.1016/j.tripleo.2011.02.034
  • Perego F, Gidaro A, Zanichelli A, et al. Life expectancy in Italian patients with hereditary angioedema due to C1-inhibitor deficiency. J Allergy Clin Immunol Pract. 2020;8(5):1772–1774. doi:10.1016/j.jaip.2020.01.007
  • Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol. 2010;126(5):918–925. doi:10.1016/j.jaci.2010.08.012
  • Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131–1140. doi:10.1056/NEJMoa1613627
  • Späth PJ, Wuthrich B, Butler R. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema – evidence of a functionally critical level of C1-inhibitor concentration. Complement. 1984;1(3):147–159. doi:10.1159/000467830
  • Valerieva A, Caccia S, Cicardi M. Recombinant human C1 esterase inhibitor (conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema. Expert Rev Clin Immunol. 2018;14(9):707–718. doi:10.1080/1744666X.2018.1503055
  • Riedl MA, Grivcheva-Panovska V, Moldovan D, et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet. 2017;390(10102):1595–1602. doi:10.1016/S0140-6736(17)31963-3
  • Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513–522. doi:10.1056/NEJMoa0805538
  • Craig T, Zuraw B, Longhurst H, et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2019;7(6):1793–1802.e2. doi:10.1016/j.jaip.2019.01.054
  • Zuraw BL, Cicardi M, Longhurst HJ, et al. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy. 2015;70(10):1319–1328. doi:10.1111/all.12658
  • Aygören-Pürsün E, Soteres DF, Nieto-Martinez SA, et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatr Allergy Immunol. 2019;30(5):553–561. doi:10.1111/pai.13060
  • Lumry WR, Martinez-Saguer I, Yang WH, et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. J Allergy Clin Immunol Pract. 2019;7(5):1610–1618.e4. doi:10.1016/j.jaip.2019.01.021
  • Ruconest (C1 esterase inhibitor [recombinant]) for intravenous use, lyophilized powder for reconstitution. package insert. Pharming Americas BV; 2020. Available from: https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf. Accessed February 3, 2023.
  • Longhurst HJ. Kallikrein inhibition for hereditary angioedema. N Engl J Med. 2017;376(8):788–789. doi:10.1056/NEJMe1611929
  • Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020;360:1–8.
  • Eurostat. Overweight and obesity - BMI statistics. Available from: https://ec.europa.eu/eurostat/statistics-explained/SEPDF/cache/12376.pdf. Accessed April 22, 2022.
  • Bernstein JA, Manning ME, Li H, et al. Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract. 2014;2(1):77–84. doi:10.1016/j.jaip.2013.09.008
  • CSL Behring. Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) for Subcutaneous Injection, Freeze-Dried Powder for Reconstitution. CSL Behring; 2022.
  • Takeda Pharmaceuticals U.S.A., Inc. Cinryze (C1 Esterase Inhibitor [Human]) for Intravenous Use, Freeze-Dried Powder for Reconstitution. Takeda Pharmaceuticals U.S.A., Inc; 2021.